Alzheimers Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence & Growing Awareness of Disease Modifying Therapies

ResearchMoz added Latest Research Report titled " Alzheimers Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Disease Modifying Therapies " to it's Large Report database.

Alzheimers Disease (AD) is an irreversible, progressive neurodegenerative disease, characterized by cognitive impairment, memory loss and functional decline. Symptoms typically begin to first occur in patients in their mid-sixties, appearing in varying stages. The pathological features of AD comprise histopathological changes within the brain. Mild Cognitive Impairment (MCI) is a heterogeneous condition between normal cognition and dementia, whereby cognitive changes in mental abilities, such as memory or thinking, are affected. Almost all cases of AD begin with MCI, but it should be noted that not all patients with MCI go on to develop AD.

Although there is a high degree of failure and uncertainty within the R&D of AD drugs, the number of drugs in the pipeline is considerable, at 559. The majority of the pipeline products are novel, and there are only seven repositioned drugs and five generic drugs. This shows progression in terms of the different molecules being developed as therapeutic agents within the AD pipeline.

Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=686320

Scope

The AD market has a lack of therapeutic options.
  • Which classes of drug dominate the market?
  • What newly approved therapies have entered the market?
  • How do the leading marketed therapies compare clinically?
  • How will the new therapies be positioned in the treatment of AD?
  • How have selected late-stage pipeline therapies performed in clinical trials?
The pipeline contains a range of molecule types and molecular targets, including those that are well established in AD, and novel, first-in-class therapies.
  • Which molecular targets appear most frequently in the pipeline?
AD clinical trials have an overall attrition rate of 94%.
  • What are the failure rates for individual Phases of clinical development?
  • How do AD clinical trial characteristics, including failure rate, duration, and size compare against respiratory and industry averages?
Read All Pharmaceutical Market Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html

Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8

2 Introduction 10
2.1 Disease Introduction 10
2.2 Epidemiology 11
2.3 Symptoms 12
2.4 Etiology and Pathophysiology 14
2.5 Diagnosis 16
2.6 Disease Stages 19
2.7 Prognosis 20
2.8 Treatment Options 21
2.8.1 Treatment Algorithm 21
2.8.2 Pharmacological Treatments 23
2.8.3 Non-pharmacological Treatments 25

3 Marketed Products 26
3.1 Overview 26
3.2 Acetylcholinesterase Inhibitors 26
3.2.1 Aricept (donepezil) - Eisai 26
3.2.2 Exelon (rivastigmine) - Novartis 27
3.2.3 Razadyne (galantamine) - Janssen 27
3.2.4 Cognex (tacrine) - Shionogi 28

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket
Albany NY - 12207
United States
Tel: +1-518-621-2074
Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Alzheimers Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence & Growing Awareness of Disease Modifying Therapies Alzheimers Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence & Growing Awareness of Disease Modifying Therapies Reviewed by Sagar Jagtap on 03:44 Rating: 5

No comments:

Powered by Blogger.